Aleksandra Tomić1, Igor Petrović2, Marina Svetel2, Valerija Dobričić1, Nataša Dragašević Mišković2, Vladimir S Kostić3. 1. Institute of Neurology, Clinical Center of Serbia, Belgrade, Serbia. 2. Institute of Neurology, Clinical Center of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 3. Institute of Neurology, Clinical Center of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia. Electronic address: vladimir.s.kostic@gmail.com.
Abstract
INTRODUCTION: Classic form of pantothenate-kinase-associated neurodegeneration (PKAN), caused by mutation in PANK2 gene, is characterized by early onset, severe neurological impairment and rapid disease progression. In less precisely described form of atypical PKAN, clinical course is associated with late onset, less severe motor impairment and slower disease evolution. The aim of this study was to assess a pattern of disease progression in atypical PKAN, by following development of specific milestones. METHODS: The clinical characteristics and the disease course of 9 genetically confirmed patients with atypical form of PKAN were evaluated. Time latencies from the disease onset to the appearance of specific clinical milestones were estimated in order to assess the disease progression. RESULTS: Most frequent disease presentation in our patients was characterized with early and prominent oromandibular dystonia (OMD), followed by severe generalized dystonia and early loss of mobility within the first five years of prolonged disease duration (18.7 ± 10.0 years). Eight out of 9 patients reached 7 significant clinical milestones (OMD, generalized dystonia, dysarthria, dysphagia, postural instability, gait difficulties, ADL dependency) in the first 4.6 years of disease course. Afterwards, a long-lasting, relatively stable period of slower progression was complicated predominantly with skeletal deformities (developed after 7.0 ± 2.8 years). CONCLUSIONS: Majority of milestones which might significantly influence functional abilities and quality of life in patients with atypical form of PKAN developed in the course of the first five years of the disease, followed by a long-lasting, relatively stable period of slower progression.
INTRODUCTION: Classic form of pantothenate-kinase-associated neurodegeneration (PKAN), caused by mutation in PANK2 gene, is characterized by early onset, severe neurological impairment and rapid disease progression. In less precisely described form of atypical PKAN, clinical course is associated with late onset, less severe motor impairment and slower disease evolution. The aim of this study was to assess a pattern of disease progression in atypical PKAN, by following development of specific milestones. METHODS: The clinical characteristics and the disease course of 9 genetically confirmed patients with atypical form of PKAN were evaluated. Time latencies from the disease onset to the appearance of specific clinical milestones were estimated in order to assess the disease progression. RESULTS: Most frequent disease presentation in our patients was characterized with early and prominent oromandibular dystonia (OMD), followed by severe generalized dystonia and early loss of mobility within the first five years of prolonged disease duration (18.7 ± 10.0 years). Eight out of 9 patients reached 7 significant clinical milestones (OMD, generalized dystonia, dysarthria, dysphagia, postural instability, gait difficulties, ADL dependency) in the first 4.6 years of disease course. Afterwards, a long-lasting, relatively stable period of slower progression was complicated predominantly with skeletal deformities (developed after 7.0 ± 2.8 years). CONCLUSIONS: Majority of milestones which might significantly influence functional abilities and quality of life in patients with atypical form of PKAN developed in the course of the first five years of the disease, followed by a long-lasting, relatively stable period of slower progression.
Authors: Marina Svetel; Aleksandra Tomić; Nataša Dragašević; Igor Petrović; Nikola Kresojević; Robert Jech; Dušan Urgošik; Isidora Banjac; Jelena Vitković; Ivana Novaković; Vladimir S Kostić Journal: J Neurol Date: 2019-08-29 Impact factor: 4.849
Authors: Pedro Enrique Labrada-Aguilera; David Armando Guach-Hevia; Carlos Rafael Almira-Gómez; Daniel Alejandro González-Lago Journal: J Med Case Rep Date: 2022-06-03
Authors: Randall D Marshall; Abigail Collins; Maria L Escolar; H A Jinnah; Thomas Klopstock; Michael C Kruer; Aleksandar Videnovic; Amy Robichaux-Viehoever; Colleen Burns; Laura L Swett; Dennis A Revicki; Randall H Bender; William R Lenderking Journal: Orphanet J Rare Dis Date: 2019-07-12 Impact factor: 4.123
Authors: Jae-Hyeok Lee; Jongkyu Park; Ho-Sung Ryu; Hyeyoung Park; Young Eun Kim; Jin Yong Hong; Sang Ook Nam; Young-Hee Sung; Seung-Hwan Lee; Jee-Young Lee; Myung Jun Lee; Tae-Hyoung Kim; Chul Hyoung Lyoo; Sun Ju Chung; Seong Beom Koh; Phil Hyu Lee; Jin Whan Cho; Mee Young Park; Yun Joong Kim; Young H Sohn; Beom Seok Jeon; Myung Sik Lee Journal: J Mov Disord Date: 2016-01-25
Authors: Yiolanda-Panayiota Christou; George A Tanteles; Elena Kkolou; Annita Ormiston; Kostas Konstantopoulos; Maria Beconi; Randall D Marshall; Horacio Plotkin; Kleopas A Kleopa Journal: Case Rep Neurol Med Date: 2017-04-16